136 related articles for article (PubMed ID: 3416552)
1. Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics.
Audet PR; Knowles JA; Troy SM; Walker BR; Morrison G
Clin Pharmacol Ther; 1988 Sep; 44(3):303-9. PubMed ID: 3416552
[TBL] [Abstract][Full Text] [Related]
2. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.
Karim A
J Clin Pharmacol; 1996 Nov; 36(11):985-97. PubMed ID: 8973987
[TBL] [Abstract][Full Text] [Related]
3. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.
Karim A; Noveck R; McMahon FG; Smith M; Crosby S; Adams M; Wilton J
J Clin Pharmacol; 1997 Apr; 37(4):267-78. PubMed ID: 9115051
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of oxaprozin.
Davies NM
Clin Pharmacokinet; 1998 Dec; 35(6):425-36. PubMed ID: 9884815
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics of oxaprozin after multiple doses].
Suwa T; Urano H; Tsuji A
Yakugaku Zasshi; 1987 Jun; 107(6):440-8. PubMed ID: 3681662
[No Abstract] [Full Text] [Related]
6. Oxaprozin disposition in renal disease.
Chiang ST; Morrison G; Knowles JA; Ruelius HW; Walker BR
Clin Pharmacol Ther; 1982 Apr; 31(4):509-15. PubMed ID: 7060332
[TBL] [Abstract][Full Text] [Related]
7. Oxaprozin dose proportionality.
Chiang ST; Lasseter KC; Fluck ER; Janssen FW; Leelavathi D; Hubsher JA
J Clin Pharmacol; 1984; 24(11-12):515-22. PubMed ID: 6511991
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.
Scavone JM; Ochs HR; Greenblatt DJ; Matlis R
Eur J Clin Pharmacol; 1988; 35(1):105-8. PubMed ID: 3220091
[TBL] [Abstract][Full Text] [Related]
9. The elimination profiles of oxaprozin in equine urine and serum after a 4.8-g dose.
Marland A; Sarkar P; Leavitt R; Lee-Ruff E; Ramnauth J
J Anal Toxicol; 1999; 23(4):242-6. PubMed ID: 10445486
[TBL] [Abstract][Full Text] [Related]
10. Oxaprozin pharmacokinetics in patients with congestive heart failure.
Ochs HR; Greenblatt DJ; Knüchel M
Arzneimittelforschung; 1986 Dec; 36(12):1837-40. PubMed ID: 3566846
[TBL] [Abstract][Full Text] [Related]
11. Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agent.
Homon CA; Fluck ER; Janssen FW; Ruelius HW
Agents Actions; 1982 Apr; 12(1-2):211-5. PubMed ID: 7080958
[TBL] [Abstract][Full Text] [Related]
12. Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.
Scavone JM; Greenblatt DJ; Matlis R; Harmatz JS
Eur J Clin Pharmacol; 1986; 31(3):371-4. PubMed ID: 3792438
[TBL] [Abstract][Full Text] [Related]
13. Oxaprozin pharmacokinetics in the elderly.
Greenblatt DJ; Matlis R; Scavone JM; Blyden GT; Harmatz JS; Shader RI
Br J Clin Pharmacol; 1985 Mar; 19(3):373-8. PubMed ID: 3986088
[TBL] [Abstract][Full Text] [Related]
14. Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects.
Lopes-de-Araújo J; Neves AR; Gouveia VM; Moura CC; Nunes C; Reis S
Pharm Res; 2016 Feb; 33(2):301-14. PubMed ID: 26350105
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction.
Brier ME; Sloan RS; Aronoff GR
Clin Pharmacol Ther; 1995 Jun; 57(6):622-7. PubMed ID: 7781261
[TBL] [Abstract][Full Text] [Related]
16. The effect of co-administered drugs on oxaprozin binding to human serum albumin.
Aubry AF; Markoglou N; Adams MH; Longstreth J; Wainer IW
J Pharm Pharmacol; 1995 Nov; 47(11):937-44. PubMed ID: 8708989
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and kinetics of oxaprozin in normal subjects.
Janssen FW; Jusko WJ; Chiang ST; Kirkman SK; Southgate PJ; Coleman AJ; Ruelius HW
Clin Pharmacol Ther; 1980 Mar; 27(3):352-62. PubMed ID: 7357792
[TBL] [Abstract][Full Text] [Related]
18. The transsynovial distribution of oxaprozin.
Kurowski M; Thabe H
Agents Actions; 1989 Jun; 27(3-4):458-60. PubMed ID: 2801338
[TBL] [Abstract][Full Text] [Related]
19. [Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application].
Mao M; Wang L; Jiang X; Yang L
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Jun; 30(3):646-50. PubMed ID: 23865335
[TBL] [Abstract][Full Text] [Related]
20. Oxaprozin: kinetic and dynamic profile in the treatment of pain.
Kean WF
Curr Med Res Opin; 2004 Aug; 20(8):1275-7. PubMed ID: 15324530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
